SLAMF7 (CS1) CHO Recombinant Cell Line (Low Expression) | 79608-L

SLAMF7 (CS1) CHO Recombinant Cell Line (Low Expression) | 79608-L | Gentaur US, UK & Europe Disrtribition

Category: CAR-T/Cell Line

Application: Useful as SLAMF7-expressing target cells in co-culture assay with SLAMF7-CAR T cells, for both SLAMF7-specific cell killing assay and cytokine production assay.

Background: The surface antigen SLAMF7 is expressed on a fraction of normal lymphocytes, including subsets of natural killer (NK) cells, T cells, and B cells. It is a robust marker of normal plasma cells and malignant plasma cells in multiple myeloma. In contrast to CD138 (the traditional plasma cell marker), CD319/SLAMF7 is much more stable and allows robust isolation of malignant plasma cells from patient samples. SLAMF7 is under intense investigation as a target for immunotherapy in multiple myeloma. It has been demonstrated that SLAMF7-CAR T cells prepared from patients and healthy donors confer potent antimyeloma reactivity. SLAMF7-CAR T cells confer fratricide of SLAMF7+/high normal lymphocytes. SLAMF7-CAR T cells represent a novel therapeutic agent for the treatment of patients with SLAMF7-expressing multiple myeloma malignancies.

Description: Recombinant clonal stable CHO cell line constitutively expressing full length human SLAMF7 protein, also known as CS1 or CD319 (Genbank #NM_021181). Surface expression of SLAMF7 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of SLAMF7 expression (High, Medium, Low) to mimic different stages of cancer target cells with various SLAMF7 expression levels.

Product Type: Cell Line

Shippement Condition: -80°C